Felix Frueh

Felix Frueh is a distinguished professional with extensive experience in pharmacology, molecular biology, and biotechnology. He is the Co-Founder and Chief Scientific Officer (CSO) at Selva Therapeutics, Inc., a San Diego-based pharmaceutical company focused on developing therapeutics for infectious diseases.12

Dr. Frueh's educational background includes studies in Pharmacology at Stanford University and a Doctor of Philosophy in Molecular Biology and Biochemistry from the University of Basel, where he graduated magna cum laude.2

Throughout his career, Felix Frueh has held several notable positions:

• Executive Partner at Opus Three LLC
• Chief Executive Officer at Intellos Health LLC
• Chief Scientific Officer at Human Longevity, Inc.
• President of Medco Research Institute at Medco Health Solutions, Inc.
• Associate Director of Genomics at the U.S. Food and Drug Administration (FDA)
• Entrepreneur-in-Residence at Third Rock Ventures

Dr. Frueh has made significant contributions to the fields of healthcare, genomics, and pharmaceuticals. At the FDA, he played a key role in developing policies related to companion diagnostics, biomarker qualification, and personalized medicine.2

Currently, as CSO at Selva Therapeutics, Dr. Frueh is involved in the development of SLV213, an orally available small-molecule antiviral therapy with activity against various viruses, including SARS-CoV-2.1

Felix Frueh is also a Fellow of the American College of Clinical Pharmacology and has held faculty positions at Georgetown University and the University of North Carolina.2